Coalition Comments on Biosimilar and Interchangeable Insulin Guidance

CAGW and coalition partners share the FDA’s deep commitment to the development of a robust biosimilars market and appreciate the Agency’s work to develop an efficient approval pathway for biosimilars to bring savings and access to America’s patients.